{"entity":{"id":"hlx26","kind":"drug","name":"HLX26","aka":["Anti-LAG-3 monoclonal Antibody Injection"],"tldr":"HLX26 is an experimental monoclonal antibody from Shanghai Henlius Biotech in phase 2 trials for non-small-cell lung cancer, aimed at LAG-3.","summary":"HLX26 is a monoclonal antibody developed by Shanghai Henlius Biotech. Its target is LAG-3 (the sponsor names LAG-3). The sponsor states: An anti-LAG-3 monoclonal antibody injection that blocks LAG-3 signalling to enhance T-cell mediated anti-tumour immunity, studied in combination with PD-1 inhibition and chemotherapy. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT05787613, plans to enrol 132 participants with primary completion was scheduled for 2026-02 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of HLX26","url":"https://clinicaltrials.gov/search?intr=HLX26"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["lag3"],"drugs":[],"companies":["henlius"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05787613"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"monoclonal antibody","mechanism":"An anti-LAG-3 monoclonal antibody injection that blocks LAG-3 signalling to enhance T-cell mediated anti-tumour immunity, studied in combination with PD-1 inhibition and chemotherapy.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/hlx26/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"lag3","kind":"target","name":"LAG-3","route":"/targets/lag3/"}],"company":[{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/"}],"trial":[{"id":"nct05787613","kind":"trial","name":"A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients","route":"/trials/nct05787613/"}]}}